Cash-Pay Healthcare Shift
Ian Lapham
@ian
· 1
−0.1%
since Oct 2
The idea
I think healthcare is splitting in two: a shrinking centralized insurance system and a growing cash-pay layer for personalized, precision care like blood panels, genomics, peptides, and longevity protocols. I own the clinics and telehealth businesses people pay directly, plus the diagnostics labs, genome sequencing, and lab-tools suppliers underneath them, with no insurers or hospital chains. I keep a slice in cash and spread bets across the stack rather than leaning on one name, planning to hold for years unless the structural shift toward cash-pay care stalls out.
What it owns
- Every personalized-care plan starts with a genome read or precision test, so these companies get paid regardless of which clinic provider wins. · NateraIt turns genetic testing into routine clinical practice across prenatal, cancer and organ health, serving as a direct measure of whether gene-level personalization is becoming standard care., IlluminaIt makes the sequencers nearly every genome read runs on, collecting revenue if genome sequencing volume keeps growing as personalized care spreads., Guardant HealthIt reads cancer from a blood draw, providing the hyper-focused testing that affluent patients will pay for as liquid biopsy gains ground in oncology clinics., Tempus AIIt is the data layer that turns test results into personalized treatment decisions, serving as the AI network that clinics sit on top of., GeneDx HoldingsIt sequences whole genomes to diagnose rare disease, demonstrating that genome reads pay for themselves in actual clinical care and real diagnosis.25%
- The infrastructure makers whose instruments and consumables every lab and sequencer depends on, providing steady ballast for long-term growth. · Thermo Fisher ScientificIt sells the instruments and consumables every lab in this ecosystem buys, providing steady anchorage while spending on diagnostics and sequencing climbs., DanaherIt owns the tools and bioprocessing businesses underlying diagnostics and personalized therapeutics, providing a second anchor for long-term infrastructure growth., Agilent TechnologiesIt supplies the analytical instruments labs use for blood chemistry and genomics, rounding out the infrastructure layer as lab testing demand expands.18%
- The consumer businesses where people pay directly for personalized care, forming the visible edge of the shift away from centralized insurance. · Hims & Hers HealthIt is the largest front door where people hand over their own money for personalized care without an insurer, directly measuring whether affluent patients are routing around the centralized system., IDEXX LaboratoriesIt supplies the testing behind pet clinics where owners already pay cash for diagnostics, while expanding into veterinary AI and deepening its diagnostics capabilities., LifeMDIt offers a smaller, purer version of direct-pay virtual care where people purchase treatment plans directly without insurance involvement., Life Time GroupIt is turning gyms into longevity clinics with blood panels and health optimization for members who pay out of pocket, targeting the top-tier personalized-care customer.18%
- The drugs people increasingly pay for directly, focused on metabolic, precision and genetic medicines tailored to individual biology. · Eli LillyIt already sells weight-loss and metabolic drugs directly to cash-paying patients, showing the clearest live example of affluent people paying out of pocket for personalized treatment., Vertex PharmaceuticalsIt built its business on drugs matched to specific genetic profiles starting with cystic fibrosis, proving that gene-targeted medicine is a durable business model., CRISPR TherapeuticsIt pursues gene editing directly with an approved therapy already on the market, representing the long-shot payoff if gene editing becomes part of routine personalized care.17%
- Cash-pay clinics route their blood panels through these companies rather than owning labs themselves, sitting at the core of direct-to-consumer testing. · Quest DiagnosticsIt runs the blood panels behind direct-to-consumer testing and collects fees regardless of whether volume comes from cash-pay startups or traditional channels., Labcorp HoldingsIt is the second half of the blood-testing backbone and operates its own direct-to-consumer testing arm, benefiting as people order their own labs outside traditional insurance., QiagenIt makes the sample-prep kits inside nearly every genetic and molecular test, so more testing volume anywhere in the stack flows through its products.14%
- Cash8%